Filing Flows › Mirum Pharmaceuticals (MIRM) › Livmarli revenue
Mirum Pharmaceuticals (MIRM) Livmarli revenue by quarter
Mirum Pharmaceuticals' Livmarli revenue was $133M in Q3 2026 (third quarter 2026), +4% from Q2 2026. Over the last 7 quarters it ranged from $73.2M (Q1 2025) to $133M (Q3 2026).
| Quarter | Livmarli revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $133M | +4% | +45% |
| Q2 2026 | $129M | +13% | +46% |
| Q1 2026 | $114M | +7% | +55% |
| Q4 2025 | $106M | +15% | — |
| Q3 2025 | $92.2M | +5% | — |
| Q2 2025 | $88.2M | +20% | — |
| Q1 2025 | $73.2M | — | — |
Q3 2026 at a glance
Mirum Pharmaceuticals, Q3 2026: revenue $186M (+40% year over year), operating margin -32.2%, net loss $40.8M, operating cash flow −$4.3M. The chart follows the revenue to costs, profit and cash.
Questions
What is Mirum Pharmaceuticals' Livmarli revenue?
Mirum Pharmaceuticals' Livmarli revenue was $133M in Q3 2026 (third quarter 2026), +4% from Q2 2026.
How has Mirum Pharmaceuticals' Livmarli revenue changed?
Over the last 7 quarters it ranged from $73.2M (Q1 2025) to $133M (Q3 2026).